Medication info

Bacrax Injection 500 mg (Acyclovir)

Prescription medicationIntravenous injection
Ingredient · strength
Acyclovir›500mg / 1 vial
Manufacturer / importer
Aprogen Pharmaceuticals Co., Ltd.
Appearance
A vial containing a white powder
Packaging
10 vials/case
Approval status
Active

MFDS item code 199700476 · Notified 1997.03.03 · Insurance code 645203971

Summary

Main use
Treatment and prevention of herpes simplex (including encephalitis and genital herpes); treatment of chickenpox and shingles
Who receives it
Adults · Children
Adult administration
○ Adults 1. Treatment of herpes simplex virus infections 1) Administer acyclovir 200 mg per dose 5 times daily at 4-hour intervals for 5 days. Treatment may be extended in severe initial infections. 2) In patients with severe immunodeficiency (e.g., after bone marrow transplantation) or gastrointestinal malabsorption, the dose may be increased to 400 mg per dose or the route of administration may be changed to intravenous injection. 3) Administration should begin as soon as possible after infection; in recurrent cases, it is preferable to begin at the first sign of prodromal symptoms or lesions. 2. Prevention of herpes simplex infections in patients with normal immune function 1) Administer this medicine 200 mg per dose 4 times daily at approximately 6-hour intervals. Alternatively, 400 mg per dose may be administered twice daily at 12-hour intervals. 2) The dose may then be reduced to 200 mg per dose 2–3 times daily after confirming its efficacy. 3) To assess the natural course of the disease, long-term treatment should be periodically interrupted every 6–12 months for evaluation. 3. Prevention of herpes simplex infections in patients with impaired immune function 1) Administer this medicine 200 mg per dose 4 times daily at approximately 6-hour intervals. 2) In patients with severe immunodeficiency (e.g., after bone marrow transplantation) or gastrointestinal malabsorption, the dose may be increased to 400 mg per dose or the route of administration may be changed to intravenous injection. 3) Administer during the period of risk of infection. 4. Treatment of herpes zoster infections 1) Administer this medicine 800 mg per dose 5 times daily at approximately 4-hour intervals, except at bedtime, for a total of 7 days. 2) Intravenous administration should be considered in patients with severe immunodeficiency or gastrointestinal malabsorption. 3) Administration should begin as soon as possible after infection; the earlier treatment is started, the better the effect. ○ Patients with renal impairment Patients with renal impairment are more likely to experience adverse reactions in the neuropsychiatric system; therefore, use caution, including by extending the dosing interval or reducing the dose. 1. Treatment of herpes simplex infections The oral dose is generally not higher than the amount that would accumulate following intravenous injection. However, in patients with severe renal impairment (creatinine clearance less than 10 mL/min), it is preferable to administer this medicine 200 mg every 12 hours. 2. Treatment of varicella-zoster virus infections In patients with severe renal impairment (creatinine clearance less than 10 mL/min), it is preferable to reduce the dose of this medicine to 800 mg per dose 3–4 times daily at approximately 6–8-hour intervals. (Injection) At each administration, the injection should be given slowly by intravenous infusion over at least 1 hour. A treatment period of 5 days is appropriate, but may be adjusted according to the patient's symptoms and healing status. Herpes simplex encephalitis is usually treated for 10 days. 1. Adults 1) Herpes simplex infections: In patients with normal or impaired immune function, administer acyclovir 5 mg/kg body weight every 8 hours. 2) Recurrent varicella-zoster virus infections: In patients with normal immune function, administer this medicine 5 mg/kg body weight every 8 hours. 3) Initial and recurrent varicella-zoster virus infections: In patients with impaired immune function, administer this medicine 10 mg/kg body weight every 8 hours. 4) Herpes simplex encephalitis: In patients with normal or impaired immune function, administer this medicine 10 mg/kg body weight every 8 hours. 5) Prevention of herpes simplex virus infections in patients with impaired immune function: Consider when oral administration is not possible, and determine the duration of administration according to the period of risk of infection. 6) Intravenous administration of acyclovir based on actual body weight in obese patients may increase plasma concentrations. Therefore, dose reduction should be considered in obese patients, especially those with renal impairment or who are elderly. 2. Patients with renal impairment are more likely to experience adverse reactions in the neuropsychiatric system; therefore, use caution during administration. The dosage is as follows. Creatinine clearance (mL/min) Dosage 25–50 Administer the recommended dose for the indication above every 12 hours 10–25 Administer the recommended dose for the indication above every 24 hours 0 (anuria)–10 For patients receiving peritoneal dialysis, administer half the recommended dose (2.5 or 5 mg/kg body weight) every 24 hours. For patients receiving hemodialysis, administer half the recommended dose (2.5 or 5 mg/kg body weight) every 24 hours and after dialysis. 4. Preparation of solution Dissolve 1 vial (containing 250 mg acyclovir) by adding 10 mL of water for injection or normal saline for infusion (0.9% w/v). Then administer intravenously using an infusion pump that allows the infusion volume to be controlled, or dilute and administer by intravenous infusion. 5. Method of administration 1) For intravenous administration using an infusion pump, administer the above acyclovir 25 mg/mL solution undiluted over at least 1 hour. 2) For diluted intravenous infusion, the acyclovir concentration should be 0.5% w/v or less. Dilute a vial containing 250 mg in at least 50 mL of solution and administer over at least 1 hour. 3) For dilution, the following infusion solutions may be used; the mixture is stable for 12 hours at room temperature (15–25℃). (1) 0.45% w/v or 0.9% w/v normal saline for infusion (2) A mixture of 0.18% w/v normal saline and 4% w/v glucose for infusion (3) A mixture of 0.45% w/v normal saline and 2.5% w/v glucose for infusion (4) Compound sodium lactate solution for infusion (Hartmann's solution) 4) After adding this medicine to the infusion solution, shake the mixture thoroughly to ensure complete mixing. 5) If cloudiness or crystals are visible in the solution before or during infusion, discard the mixture. Do not refrigerate the solution.
Child administration
○ Children 1. Treatment of herpes simplex infections and prevention of herpes simplex infections in patients with impaired immune function Age 2 years and older: Same as for adults. Under 2 years: Administer 1/2 the adult dose. 2. Treatment of chickenpox in children aged 2 years and older: Administer 20 mg per kg of body weight per dose (maximum 800 mg per dose) 4 times daily for 5 days. (Injection) Children aged 3 months~12 years with herpes simplex (excluding herpes simplex encephalitis) or varicella-zoster virus infection: Administer 250 mg per ㎡ of body surface area every 8 hours. Children aged 3 months~12 years who are immunocompromised with varicella-zoster infection or have herpes simplex encephalitis: If renal function is normal, administer 500 mg per ㎡ of body surface area every 8 hours. Adjust the dose appropriately according to the degree of impairment in pediatric patients with renal impairment.

Ingredients

Manufacturer
Aprogen Pharmaceuticals Co., Ltd.

Efficacy & effects

Treatment and prevention of herpes simplex (including encephalitis and genital herpes); treatment of chickenpox and shingles

  • Genital herpes
  • herpes simplex virus infections
  • varicella-zoster virus infections
  • acute pain
  • chickenpox
  • severe primary genital herpes
  • recurrent varicella-zoster virus infections
  • herpes simplex encephalitis
View approved original text

This medication is available in various forms and is primarily used for the treatment of viral infections. It is effective in treating and preventing infections caused by the herpes simplex virus that affect the skin and mucous membranes, particularly aiding in both primary and recurrent genital herpes. It is also used to treat infections caused by the varicella-zoster virus, effective in alleviating acute pain. It is used in the treatment of chickenpox in children over the age of 2, and is utilized for severe viral infections in both immunocompetent patients and those with compromised immune function. This drug aids not only in herpes simplex and varicella-zoster virus infections but also in the treatment of herpes simplex encephalitis. Therefore, it is widely used in the treatment of viral infections.

How it is given

Adult administration

○ Adults 1. Treatment of herpes simplex virus infections 1) Administer acyclovir 200 mg per dose 5 times daily at 4-hour intervals for 5 days. Treatment may be extended in severe initial infections. 2) In patients with severe immunodeficiency (e.g., after bone marrow transplantation) or gastrointestinal malabsorption, the dose may be increased to 400 mg per dose or the route of administration may be changed to intravenous injection. 3) Administration should begin as soon as possible after infection; in recurrent cases, it is preferable to begin at the first sign of prodromal symptoms or lesions. 2. Prevention of herpes simplex infections in patients with normal immune function 1) Administer this medicine 200 mg per dose 4 times daily at approximately 6-hour intervals. Alternatively, 400 mg per dose may be administered twice daily at 12-hour intervals. 2) The dose may then be reduced to 200 mg per dose 2–3 times daily after confirming its efficacy. 3) To assess the natural course of the disease, long-term treatment should be periodically interrupted every 6–12 months for evaluation. 3. Prevention of herpes simplex infections in patients with impaired immune function 1) Administer this medicine 200 mg per dose 4 times daily at approximately 6-hour intervals. 2) In patients with severe immunodeficiency (e.g., after bone marrow transplantation) or gastrointestinal malabsorption, the dose may be increased to 400 mg per dose or the route of administration may be changed to intravenous injection. 3) Administer during the period of risk of infection. 4. Treatment of herpes zoster infections 1) Administer this medicine 800 mg per dose 5 times daily at approximately 4-hour intervals, except at bedtime, for a total of 7 days. 2) Intravenous administration should be considered in patients with severe immunodeficiency or gastrointestinal malabsorption. 3) Administration should begin as soon as possible after infection; the earlier treatment is started, the better the effect. ○ Patients with renal impairment Patients with renal impairment are more likely to experience adverse reactions in the neuropsychiatric system; therefore, use caution, including by extending the dosing interval or reducing the dose. 1. Treatment of herpes simplex infections The oral dose is generally not higher than the amount that would accumulate following intravenous injection. However, in patients with severe renal impairment (creatinine clearance less than 10 mL/min), it is preferable to administer this medicine 200 mg every 12 hours. 2. Treatment of varicella-zoster virus infections In patients with severe renal impairment (creatinine clearance less than 10 mL/min), it is preferable to reduce the dose of this medicine to 800 mg per dose 3–4 times daily at approximately 6–8-hour intervals. (Injection) At each administration, the injection should be given slowly by intravenous infusion over at least 1 hour. A treatment period of 5 days is appropriate, but may be adjusted according to the patient's symptoms and healing status. Herpes simplex encephalitis is usually treated for 10 days. 1. Adults 1) Herpes simplex infections: In patients with normal or impaired immune function, administer acyclovir 5 mg/kg body weight every 8 hours. 2) Recurrent varicella-zoster virus infections: In patients with normal immune function, administer this medicine 5 mg/kg body weight every 8 hours. 3) Initial and recurrent varicella-zoster virus infections: In patients with impaired immune function, administer this medicine 10 mg/kg body weight every 8 hours. 4) Herpes simplex encephalitis: In patients with normal or impaired immune function, administer this medicine 10 mg/kg body weight every 8 hours. 5) Prevention of herpes simplex virus infections in patients with impaired immune function: Consider when oral administration is not possible, and determine the duration of administration according to the period of risk of infection. 6) Intravenous administration of acyclovir based on actual body weight in obese patients may increase plasma concentrations. Therefore, dose reduction should be considered in obese patients, especially those with renal impairment or who are elderly. 2. Patients with renal impairment are more likely to experience adverse reactions in the neuropsychiatric system; therefore, use caution during administration. The dosage is as follows. Creatinine clearance (mL/min) Dosage 25–50 Administer the recommended dose for the indication above every 12 hours 10–25 Administer the recommended dose for the indication above every 24 hours 0 (anuria)–10 For patients receiving peritoneal dialysis, administer half the recommended dose (2.5 or 5 mg/kg body weight) every 24 hours. For patients receiving hemodialysis, administer half the recommended dose (2.5 or 5 mg/kg body weight) every 24 hours and after dialysis. 4. Preparation of solution Dissolve 1 vial (containing 250 mg acyclovir) by adding 10 mL of water for injection or normal saline for infusion (0.9% w/v). Then administer intravenously using an infusion pump that allows the infusion volume to be controlled, or dilute and administer by intravenous infusion. 5. Method of administration 1) For intravenous administration using an infusion pump, administer the above acyclovir 25 mg/mL solution undiluted over at least 1 hour. 2) For diluted intravenous infusion, the acyclovir concentration should be 0.5% w/v or less. Dilute a vial containing 250 mg in at least 50 mL of solution and administer over at least 1 hour. 3) For dilution, the following infusion solutions may be used; the mixture is stable for 12 hours at room temperature (15–25℃). (1) 0.45% w/v or 0.9% w/v normal saline for infusion (2) A mixture of 0.18% w/v normal saline and 4% w/v glucose for infusion (3) A mixture of 0.45% w/v normal saline and 2.5% w/v glucose for infusion (4) Compound sodium lactate solution for infusion (Hartmann's solution) 4) After adding this medicine to the infusion solution, shake the mixture thoroughly to ensure complete mixing. 5) If cloudiness or crystals are visible in the solution before or during infusion, discard the mixture. Do not refrigerate the solution.

Child administration

○ Children 1. Treatment of herpes simplex infections and prevention of herpes simplex infections in patients with impaired immune function Age 2 years and older: Same as for adults. Under 2 years: Administer 1/2 the adult dose. 2. Treatment of chickenpox in children aged 2 years and older: Administer 20 mg per kg of body weight per dose (maximum 800 mg per dose) 4 times daily for 5 days. (Injection) Children aged 3 months~12 years with herpes simplex (excluding herpes simplex encephalitis) or varicella-zoster virus infection: Administer 250 mg per ㎡ of body surface area every 8 hours. Children aged 3 months~12 years who are immunocompromised with varicella-zoster infection or have herpes simplex encephalitis: If renal function is normal, administer 500 mg per ㎡ of body surface area every 8 hours. Adjust the dose appropriately according to the degree of impairment in pediatric patients with renal impairment.

Precautions

This medication should not be used by patients who have had an allergic reaction to this medication or its components. Patients with impaired kidney function, compromised liver function, young children, and the elderly should use this medication with extra caution. When using this medication, severe allergic reactions or shock may occur rarely, so if symptoms such as low blood pressure, shortness of breath, or chest tightness appear, usage should be stopped immediately and healthcare professionals should be informed. Skin reactions such as rashes, hives, or severe dermatitis may occur, so use should be discontinued and medical advice sought if these symptoms appear. Neurological symptoms such as confusion, drowsiness, seizures, or hallucinations may manifest, especially in patients with poor kidney function or the elderly, and these symptoms may occur more frequently. It may put a strain on the kidneys, potentially resulting in urination abnormalities or increased kidney function values, thus regular check-ups are necessary. Liver function abnormalities or jaundice symptoms may occur, requiring careful monitoring of liver health. Gastrointestinal symptoms, including abdominal pain, nausea, vomiting, or constipation, may manifest, and if symptoms are severe, use should be discontinued. Adequate hydration is important when using this medication, especially when using high doses to prevent dehydration and reduce kidney toxicity by drinking plenty of water. Women who are pregnant or may become pregnant should carefully consider the risks and benefits of using this medication, and breastfeeding should be discontinued because this medication may be passed into breast milk. This medication may interact with other drugs, so patients taking other medications must inform their doctor or pharmacist. In case of overdose, neurological symptoms and kidney damage may occur, so if overdose is suspected, immediate medical attention is required, and treatments such as hemodialysis may be necessary. This medication is most effective when used as early as possible after symptom onset, and if symptoms do not improve or worsen during the treatment period, alternative treatment options should be considered.

Side effects

  • Anaphylactic shock
  • anaphylactic reaction
  • hypotension
  • shortness of breath
  • chest tightness
  • photophobia
  • fixed drug eruption
  • rash
  • fever
  • vesicles
Show 133 more
  • urticarial erythema
  • urticaria
  • alopecia
  • erythema multiforme
  • mucous membrane syndrome
  • toxic epidermal necrolysis
  • consciousness disturbance
  • derealization
  • concentration impairment
  • aggressive behavior
  • depersonalization
  • agitation
  • ataxia
  • coma
  • confusion
  • delirium
  • stuttering
  • encephalopathy
  • hallucinations
  • psychosis
  • seizures
  • drowsiness
  • tremors
  • excitement
  • forgetfulness
  • insomnia
  • anxiety
  • talking to oneself
  • paresthesia
  • ataxia
  • inability to walk
  • involuntary movements
  • nystagmus
  • renal failure
  • crystalluria
  • increased BUN
  • elevated serum creatinine
  • hematuria
  • proteinuria
  • urinary red blood cell casts
  • pyuria
  • leukocytoclastic vasculitis
  • lymphadenopathy
  • bleeding
  • purpura
  • anemia
  • leukopenia
  • leukocytosis
  • eosinophilia
  • lymphocytosis
  • thrombocytosis
  • granulocytopenia
  • thrombocytopenia
  • basophilia
  • hepatitis
  • liver dysfunction
  • jaundice
  • abnormal liver function tests
  • hepatomegaly
  • gastritis
  • thirst
  • constipation
  • acute pancreatitis
  • diarrhea
  • loose stools
  • epigastric pain
  • stomach pain
  • abdominal pain
  • nausea
  • vomiting
  • dyspepsia
  • loss of appetite
  • glossitis
  • fever
  • peripheral edema
  • syncope
  • pallor
  • muscle weakness
  • malaise
  • generalized fatigue
  • headache
  • arthralgia
  • myalgia
  • arrhythmia
  • chest pain
  • hypertension
  • hypotension
  • tachycardia
  • palpitations
  • urinary obstruction
  • dysuria
  • glucosuria
  • pneumonia
  • pharyngitis
  • pleural effusion
  • pain
  • hearing loss
  • conjunctivitis
  • visual disturbances
  • taste disorders
  • sweating
  • hyponatremia
  • decreased serum protein
  • decreased serum albumin
  • increased serum potassium
  • decreased serum potassium
  • agitation
  • coma
  • somnolence
  • nonsensical speech
  • speech disorders
  • numbness in the limbs
  • numbness of the tongue and extremities
  • generalized malaise
  • bipolar disorder
  • emotional instability
  • concentration impairment
  • depersonalization
  • forgetfulness
  • insomnia
  • ataxia
  • talking to oneself
  • paresthesia
  • gait abnormalities
  • involuntary movements
  • dysuria
  • edema
  • sensitivity to cold
  • feeling of chest tightness
  • vascular pain
  • rapid vascular weakening
  • ulcers
  • inflammation

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in an airtight container to prevent exposure to air and should be kept at a temperature below 25 degrees Celsius. This storage method helps maintain the medication's efficacy for a longer period.

Appearance and packaging

Appearance

A vial containing a white powder

Package unit

10 vials/case

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.